Eli Lilly and Novo Nordisk Hold Up in the GLP-1 Boom, While Investors Look to Adjacent Medical-Industry Plays

GLP-1 medicines, now central to treatment of type 2 diabetes and obesity, continue to draw heavy investor attention, and Eli Lilly and Novo Nordisk remain the industry’s core profit engines. In a recent market piece published by Yahoo Finance, the argument was not that the category’s leaders are breaking, but that the “obvious” winners may not be the only way to play expanding demand.

The commentary frames GLP-1 use as a rapidly growing market, emphasizing that these drugs have proven effective across conditions such as diabetes and obesity. That basic demand thesis has been echoed across mainstream financial media as the category expands from injectable therapies toward more convenient formats, including oral options. In other words, even if Lilly and Novo Nordisk stay in pole position, the ecosystem around the drugs may still be where incremental upside appears.

A key theme in broader reporting is that GLP-1 obesity drug momentum is shifting toward a new phase in 2026, when “obesity pills” are expected to reshape the competitive landscape and patient experience. CNBC reported that the category’s next chapter may be driven by tablets that could improve convenience relative to injections, potentially changing prescribing patterns and expanding the accessible patient pool. That matters to the companies closest to manufacturing and distribution, but also to the businesses that support day-to-day treatment delivery.

The competitive pressure between Lilly and Novo Nordisk is also increasingly tied to formulation and convenience. CNBC has reported that Novo Nordisk’s earlier steps on GLP-1 pills are forcing investors to revisit Eli Lilly’s dominance narrative, after Novo gained attention for its Wegovy pill progress. The point for markets is that GLP-1 leadership may not be a single-lane story anymore, and that product format and rollout timing can influence how investors value each company’s medium-term trajectory.

Against that backdrop, the Yahoo Finance piece said Lilly and Novo Nordisk are “fine,” but it urged readers not to overlook other publicly traded options, specifically two medical-industry stocks described as better suited to capture the GLP-1 boom’s spillover effects. The post, however, does not provide enough detail in the available text to identify those two companies or to specify what exact GLP-1 linkage the author is relying on.

Still, the direction of travel is consistent with how GLP-1 investment narratives often evolve. As patients move from early adoption into mass treatment, the commercial picture extends beyond the drug label itself. Companies that provide enabling hardware and services, as well as those embedded in distribution, adherence, and administration, can see demand indirectly accelerate as prescription volumes rise.

For investors, there is also a practical question: how much of the category’s value is already priced into the biggest names versus how much sits in adjacent beneficiaries. The Yahoo Finance commentary appears to take a portfolio-construction view, suggesting that even within a strong sector like GLP-1 therapeutics, the “best” exposure may differ depending on where you believe incremental demand shows up first.

Even so, without the names and the underlying rationale being visible in the available material, it remains unclear what those two highlighted medical-device stocks do, how directly their demand ties to GLP-1 prescriptions, and whether their financial momentum is expected to track the drug makers or merely the broader obesity/diabetes treatment wave. Investors would need to review the full article and confirm any stated links to current contracts, order trends, or technology adoption timelines before drawing conclusions.

Looking ahead, the market’s watch list is likely to include both drug-formulation progress and the broader adoption curve for obesity and diabetes treatments. For Lilly and Novo Nordisk, developments that affect how quickly oral or more convenient therapies scale could influence expectations for the category’s growth rate. For the medical-industry “adjacent” plays hinted at in the Yahoo Finance piece, the next markers to follow would be evidence of whether business activity is rising alongside GLP-1 prescription growth, rather than just benefiting from the theme.